Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Brain Networks Involved in Inner World Control

NCT07469631 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-05-01
Last updated
2026-03-13

Condition(s) studied

Neurosciences

Investigational drug(s) / intervention(s)

Neuropsychological evaluation, questionnaires, and training on the tasks that will be performed in the MRI.MRI visits

Neuropsychological evaluation, questionnaires, and training on the tasks that will be performed in the MRI.: The neuropsychological/questionnaires evaluation is a 3 hour visit during which participants will complete a battery of neuropsychological tests and respond to questionnaires assessing their capacity for inner speech and self representation. In a second 30 minute visit, they will be trained on the tasks (inner speech tasks and control tasks) that they will perform in the MRI.

MRI visits: There will be two 2 hour MRI visits. During the first visit, participants will perform the learned task conditions designed to test the control of inner speech; during the second visit, they will perform the control conditions and an anatomical MRI will be acquired, as well as a resting state fMRI scan to study functional connectivity and a DTI scan to study structural connectivity

Study summary

Inner speech (the "little voice" in our heads) plays a central role in our ability to perform complex cognitive tasks such as problem solving, reading, writing, thinking, and self awareness. It is estimated that at least a quarter of our lives is accompanied by inner speech, whether deliberate (mentally making a list) or more spontaneous (mind wandering). Although central to human life, its neural bases remain poorly understood. It has been recently discovered a single region in the human prefrontal cortex absent in nonhuman primates, the prefrontal operculum (PFO), which shows a pattern of functional connectivity with the rest of the brain that could give it a role in controlling inner speech. The aim of this research is to understand how the brain generates and controls inner speech using functional magnetic resonance imaging (fMRI). Dysfunctions of inner speech, especially when spontaneous and wandering, can lead to severe mental disorders (anxiety disorders, depression, verbal auditory hallucinations). It is therefore crucial to identify the role of the PFO and the networks that involve it, particularly the precuneus, in controlling inner speech across its different manifestations. The first hypothesis is that the PFO and the networks that include it play a key role in the cognitive control of inner speech in participants who experience inner speech. The second hypothesis is that the PFO is hyperactive in participants who lack inner speech (so called aphantasics), preventing the production of inner speech. To test these hypotheses, participants will complete a battery of well established questionnaires to determine whether they can produce inner speech (control participants with typical inner speech) or not (aphantasic participants). These participants will take part in an fMRI study contrasting tasks that recruit inner speech that do or do not require cognitive control. The third hypothesis is that the extent of inner speech depends on the capacity for self representation, and thus on the interaction between the PFO and the precuneus. The investigator hypothesize a positive correlation between inner speech ability and self representation capacity, associated with stronger functional connectivity between the PFO and the precuneus. The investigator predict reduced self representation in aphantasic participants. To test this, participants will complete a battery of well established questionnaires. The investigator will compute correlations between 1) behavioral performance on inner speech tasks and questionnaire scores, and 2) the network measures identified in fMRI (task activation and connectivity) and questionnaire scores.

Eligibility

Sex
ALL
Min age
20 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Registered with the national Social Security system. * Right handed. * Native French speakers. * Visual acuity sufficient to read stimuli (contact lenses permitted). * Willing to follow MRI instructions and recommendations. * Able to provide written informed consent to participate in the study. Exclusion Criteria: * History of known neurological or psychiatric disorder. * Respiratory pathologies (in particular persistent asthma) or cardiovascular diseases. * Speech or language disorders (aphasia, dysphasia, dysarthria, stuttering, etc.). * Hearing impairments. * Memory disorders. * Cognitive impairments limiting understanding of instructions. * Recent use of psychotropic medications. Major treatments not permitted in this research include psychotropic drugs that can alter perception, sensations, mood, consciousness, or behavior, for example: * Antipsychotics (valproic acid, amisulpride, aripiprazole, clozapine, cyamemazine, haloperidol, loxapine, olanzapine, risperidone). * Antidepressants (amitriptyline, citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, mianserin, mirtazapine, nortriptyline, paroxetine, sertraline, venlafaxine). * Anxiolytics. * Pregnant or breastfeeding women. No pregnancy test will be performed at inclusion; pregnancy must be reported by self declaration. * Minors. * Persons deprived of liberty by judicial or administrative decision. * Persons admitted to a health or social institution for reasons other than research. * Adults under legal protection measures (guardianship, conservatorship). * Persons not affiliated with a social security scheme or with a similar scheme only. * Participants refusing to be informed in case of an incidental finding on MRI. * Contraindications to fMRI, including: * Pacemaker, neurosensory stimulator, or implantable defibrillator: risk of transient or permanent device damage or heating of metal parts. In patients with such devices, scanning should be performed only if absolutely necessary, with the patient's informed agreement after clear explanation of risks, and in the presence of a physician from the referring service. * Metallic prostheses: potential for significant artifacts depending on size and ferromagnetic properties; certain neurosurgical clips or cardiac valves may pose problems and require verification of the exact implanted model. * Ferromagnetic ocular or intracranial foreign bodies near nervous structures: risk of displacement and ocular or cerebral injury. * Cochlear implants: risk of demagnetization, electrode heating, and artifacts. * Neurosurgical shunt valves. * Claustrophobic participants. * Dental appliances.

Primary outcome measure(s)

  • To assess the role of the prefrontal operculum (PFO) (and the brain network to which it belongs) — at 60 days
    MRI measurement (without contrast injection) according to the conditions of inner speech used

Trial sites (2)

FacilityCityRegionStatus
CRNL, IMPACT team, INSERM U1028 Bron France
Plateforme PRIMAGE, Cermep Bron France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07469631 on ClinicalTrials.gov ↗ ← All trials in France